Finch TherapeuticsNASDAQ: FNCH

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and Crohn's disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.

Finch Therapeutics is in the Healthcare sector

Finch Therapeutics is in the Biotechnology industry

Finch Therapeutics is headquartered in United States

Finch Therapeutics initial public offering (IPO) was on 19 March 2021

https://www.finchtherapeutics.com

No, Finch Therapeutics is not included in the S&P 500 index

No, Finch Therapeutics is not included in the NASDAQ 100 index

No, Finch Therapeutics is not included in the Dow Jones index